Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | SHBG | P04278 | 1/20 | 0.33 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13500021 | 0.91 | CYP1A2 (0.48) | CYP1A2USP2HTTHSD17B10SMN1; SMN2 | |
| SCHEMBL21358600 | 0.90 | NFE2L2 (0.37) | CYP1A2USP2SMN1; SMN2NFE2L2PRMT5 | |
| SCHEMBL13459004 | 0.85 | USP2 (0.46) | CYP1A2USP2SMN1; SMN2NFE2L2PRMT5 | |
| SCHEMBL28432329 | 0.83 | HSD17B10 (0.47) | CYP1A2HSD17B10SMN1; SMN2NFE2L2METAP2 | |
| SCHEMBL6937266 | 0.78 | CYP1A2 (0.54) | CYP1A2SMN1; SMN2NFE2L2 | |
| SCHEMBL7907019 | 0.78 | HSD17B10 (0.45) | CYP1A2USP2HTTHSD17B10METAP2 | |
| SCHEMBL13459028 | 0.76 | USP2 (0.49) | CYP1A2USP2SMN1; SMN2 | |
| SCHEMBL14398008 | 0.76 | CYP1A2 (0.46) | CYP1A2METAP2SHBG | |
| SCHEMBL75092 | 0.76 | CYP1A2 (0.50) | CYP1A2SMN1; SMN2NFE2L2 | |
| SCHEMBL16404829 | 0.76 | CYP1A2 (0.50) | CYP1A2SMN1; SMN2NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8829229-B2 | Polyol ethers and process for making them | DOW GLOBAL TECHNOLOGIES LLC (US) | 2014-09-09 | — | — | US | disclosed |
| US-20100048940-A1 | reductive etherification of a polyol with an aldehyde or ketone using a hydrogenation catalyt; resulting compounds have use as solvents, surfactants, degreasers, wetting agents, emulsifying agents, lubricants, and intermediates for surfactants; polyols can be from renewable raw materials | DOW GLOBAL TECHNOLOGIES LLC | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048940-A1 | reductive etherification of a polyol with an aldehyde or ketone using a hydrogenation catalyt; resulting compounds have use as solvents, surfactants, degreasers, wetting agents, emulsifying agents, lubricants, and intermediates for surfactants; polyols can be from renewable raw materials | RNF114, USP14, USP13 | CYP1A2 551/4885USP2 70/4885HTT 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.